Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

SAN FRANCISCO, July 31, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2014.

Cash and investments in marketable securities at June 30, 2014 were $301.4 million as compared to $309.1 million at March 31, 2014."The second half of 2014 will be an exciting time for Nektar as we look forward to significant milestones for a number of our late-stage clinical programs," said Howard W. Robin, President and Chief Executive Officer of Nektar. "The first of these is the potential US and EU approvals of Movantik™ with our partner AstraZeneca. If approved, Movantik would be the first oral targeted therapy approved for opioid induced constipation, a debilitating condition that occurs in up to 80%* of the 69 million chronic pain patients worldwide. Our partner Baxter has completed dosing in their Phase 3 study for BAX 855, a longer-acting PEGylated Factor VIII therapy to treat hemophilia A and plans to file the BLA in the U.S. by the end of this year. In our proprietary pipeline, we are on track for topline results from the Phase 3 breast cancer study for NKTR-102 in Q1 2015."

Revenue in the second quarter of 2014 was $28.5 million as compared to $33.9 million in the second quarter of 2013. Year-to-date revenue for 2014 was $48.3 million as compared to $56.9 million in the first half of 2013.  The decrease in revenue in the second quarter and first half of 2014 as compared to the same periods in 2013 is primarily due to decreased manufacturing activity.  Revenue included non-cash royalty revenue, related to our 2012 royalty monetization, of $4.8 million and $10.6 million in the second quarter and first half of 2014, respectively, and $3.8 million and $8.2 million in the second quarter and first half of 2013, respectively. This non-cash royalty revenue is offset by non-cash interest exp
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... -- E-QURE Corp (OTCQB: EQUR), today announced that Ron ... July 9, 2015. DATE: Thursday, July 9, 2015 ... This will be a live, interactive online event ... in real-time - both in the presentation hall as ... are not able to join the event live on ...
(Date:7/6/2015)... , July 6, 2015 Moerae ... developing novel therapeutics that target inflammation and fibrosis, ... , M.D., PhD, as Chief Medical Officer. ... clinical development strategy and programs, which include a ... inflammatory and fibrotic conditions.  Bill is an accomplished ...
(Date:7/6/2015)... July 6, 2015  Impax Laboratories, Inc. (NASDAQ: ... Ph.D. has resigned from the Company,s Board of Directors ... was a co-founder of Impax in 1995 and served ... October 2006 until April 2014. Logo - ... Impax,s President and Chief Executive Officer stated, "We wish ...
Breaking Medicine Technology:E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9 2Moerae Matrix, Inc. (Moerae) Appoints Bill Bradford, M.D., PhD, as Chief Medical Officer 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 3Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 4Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 5
... Osteotech, Inc. (Nasdaq: OSTE ), a leader ... healing, today reported financial results for the third quarter ... of 2009, our focus was on the release of ... FacetLinx(TM) Fusion Technology and Plexur M® Innovative Grafting," said ...
... Calif., Nov. 5 Renee Cobos, MD, a board ... University of California, Irvine, announced today that her patients ... system, which is approved for skin tightening and contouring, ... efficacy and improves patient comfort. , "Thermage has ...
Cached Medicine Technology:Osteotech Reports Third Quarter 2009 Financial Results 2Osteotech Reports Third Quarter 2009 Financial Results 3Osteotech Reports Third Quarter 2009 Financial Results 4Osteotech Reports Third Quarter 2009 Financial Results 5Osteotech Reports Third Quarter 2009 Financial Results 6Osteotech Reports Third Quarter 2009 Financial Results 7Osteotech Reports Third Quarter 2009 Financial Results 8Orange County Dermatologist Garners Outstanding Results With New Thermage CPT(R) 2
(Date:7/6/2015)... ... July 06, 2015 , ... Thanks to donations and ... Hospice received the Music & Memory Certification for hospice patients and adult day center ... music not only to patients but also to their families and volunteers. Music & ...
(Date:7/5/2015)... ... ... City Sports, the Boston-based specialty sporting goods retailer, has renewed their partnership ... this summer with ethos, the owner and operator of the Boston Triathlon. , The ... at the North End Greenway. The event will help new triathletes prepare for the ...
(Date:7/5/2015)... ... ... Women’s Excellence in Wellness, powered by Movestrong is offering a student special ... months of unlimited classes for just $65. Student ID is needed at registration. , ... in Lake Orion. , Women’s Excellence is the most comprehensive obstetric ...
(Date:7/4/2015)... ... July 04, 2015 , ... Earlier in 2015, on ... an annual member survey , detailing the most common plastic surgery and minimally ... that raw data down into charts detailing demographic trends and regional preferences. With ...
(Date:7/4/2015)... ... July 04, 2015 , ... Tyler Boden, Project ... technical sales expertise from the North American Board of Certified Energy Practitioners (NABCEP®), ... most highly respected and well established national certification organization for renewable energy professionals. ...
Breaking Medicine News(10 mins):Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 4Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 3Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 2Health News:The ‘South Atlantic’ Frequently Chooses Tummy Tuck for Plastic Surgery, Jacksonville, FL, Doctor Notes 3Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 2Health News:Local Solar Professional Earns Industry's Most Prestigious Certification 3
... of individuals who suffered from suicidal thoughts and erratic behavior ... ... Mineola, N.Y. (Lexis Nexis) August 5, 2008 - ... personal injury law firm Sanders Viener Grossman LLP, today announced ...
... TRAIT , A new study suggests that people who ... or phenotype that causes them to have poorer asthma ... Researchers from Quebec, Canada compared pulmonary function changes, methacholine ... circumference, and waist-to-hip ratio of 44 obese subjects with ...
... Medicare Regulation Protects, NC Seniors, Access to Quality ... Quality,Nursing Home Care today thanked North Carolina Senators Elizabeth ... bipartisan effort in,Congress to stop the Bush Administration from ... Medicare-funded nursing home care by $5,billion over the next ...
... 4, 2008 - A recent study published in ... (ESAs), a widely used drug to treat anemia, may ... patients. In the study, 323 multiple myeloma patients were ... 1988 to 2007. The investigators reviewed their medical records ...
... 4 Another Eniva nutraceutical moves,to the ... excellent quality and,valid claims. Eniva,s Efacor has ... standards from ConsumerLab.com. ConsumerLab.com,(CL) has long been ... and,quality among nutritional products. CL,s stringent testing ...
... - Total revenue increased 11 percent ... management segment revenue represented 44 percent of total revenue, compared ... - Gross margin rose to 29.4 percent from 28 percent ... share repurchase plan, MINNEAPOLIS, Aug. 4 Health Fitness,Corporation (OTC Bulletin Board: HFIT), a ...
Cached Medicine News:Health News:New York-Based Sanders Law Firm Files Five Product Liability Lawsuits Against Pfizer on Behalf of Chantix™ Plaintiffs 2Health News:Chest Journal: August news briefs 2Health News:Dole, Burr Praised for Helping Lead Senate Effort to Stop $21.8 Million North Carolina Medicare Cuts 2Health News:Treatment with anti-anemia drugs may not be safe for multiple myeloma patients 2Health News:Eniva USA Efacor(R) Fish Oil (Non-Fishy Lemon Taste) Receives ConsumerLab.com Seal of Approval 2Health News:HealthFitness Announces 2008 Second Quarter Results 2Health News:HealthFitness Announces 2008 Second Quarter Results 3Health News:HealthFitness Announces 2008 Second Quarter Results 4Health News:HealthFitness Announces 2008 Second Quarter Results 5Health News:HealthFitness Announces 2008 Second Quarter Results 6Health News:HealthFitness Announces 2008 Second Quarter Results 7Health News:HealthFitness Announces 2008 Second Quarter Results 8Health News:HealthFitness Announces 2008 Second Quarter Results 9Health News:HealthFitness Announces 2008 Second Quarter Results 10
... The ADVIA 120 Hematology System gets ... right the first time, with a ... systems. Results are more accurate, physicians ... more effective. The ADVIA 120 Hematology ...
The Advia 60 is designed to deliver powerful performance in a small package....
AcT 5diff OV enables low-volume labs to advance to 5-part differential analysis at an affordable price. This analyzer delivers accurate test results and a user-friendly software interface in a compac...
... HmX offers three-dimensional VCS ... specificity and efficiency in ... reticulocyte analysis. With its ... dependability, HmX is an ...
Medicine Products: